Beauty Health Company (SKIN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

SKIN Stock Forecast


Beauty Health Company stock forecast is as follows: an average price target of $1.00 (represents a -31.51% downside from SKIN’s last price of $1.46) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

SKIN Price Target


The average price target for Beauty Health Company (SKIN) is $1.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential -31.51% downside from SKIN's last price of $1.46.

SKIN Analyst Ratings


Buy

According to 3 Wall Street analysts, Beauty Health Company's rating consensus is 'Buy'. The analyst rating breakdown for SKIN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 1 'Hold' (33.33%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

Beauty Health Company Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 09, 2024Korinne WolfmeyerPiper Sandler$1.00$1.14-12.28%-31.51%
May 10, 2024Korinne WolfmeyerPiper Sandler$2.50$3.26-23.31%71.23%
Mar 13, 2024Korinne WolfmeyerPiper Sandler$3.00$4.25-29.41%105.48%
Mar 13, 2024Jonathan BlockStifel Nicolaus$4.00$4.25-5.88%173.97%
Apr 28, 2022Piper Sandler$26.00$13.1497.86%1680.82%

The latest Beauty Health Company stock forecast, released on Aug 09, 2024 by Korinne Wolfmeyer from Piper Sandler, set a price target of $1.00, which represents a -12.28% decrease from the stock price at the time of the forecast ($1.14), and a -31.51% decrease from SKIN last price ($1.46).

Beauty Health Company Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$2.63
Last Closing Price$1.46$1.46$1.46
Upside/Downside-100.00%-100.00%80.14%

In the current month, the average price target of Beauty Health Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Beauty Health Company's last price of $1.46. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024Cowen & Co.HoldHoldHold
Aug 12, 2024Cowen & Co.HoldHoldHold
Aug 09, 2024Piper SandlerUnderweightUnderweightHold
Jul 11, 2024Sandler O'NeillBuyBuyHold
Jul 11, 2024Sandler O'NeilUnderperformUnderperformHold
May 13, 2024Cowen & Co.HoldHoldHold
May 10, 2024Piper SandlerUnderweightUnderweightHold
Mar 13, 2024Piper SandlerHoldHoldHold
Mar 13, 2024Piper SandlerUnderweightUnderweightHold
Nov 14, 2023Raymond JamesUnderperformDowngrade
Mar 01, 2023Piper SandlerBuyBuyHold
Apr 28, 2022Piper SandlerOverweightOverweightHold

Beauty Health Company's last stock rating was published by Cowen & Co. on Nov 13, 2024. The company gave SKIN a "Hold" rating, the same as its previous rate.

Beauty Health Company Financial Forecast


Beauty Health Company Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Revenue------------$96.80M$97.40M$117.48M$86.30M$98.13M$88.79M$103.54M$75.42M$77.89M$68.15M$66.51M-
Avg Forecast$105.40M$101.50M$98.20M$90.40M$86.27M$82.54M$88.02M$77.07M$77.39M$73.65M$98.49M$80.56M$87.22M$116.22M$114.89M$90.35M$94.73M$80.56M$83.94M$68.15M$71.10M$58.05M$49.21M$44.10M
High Forecast$110.43M$106.34M$102.88M$94.71M$90.39M$86.47M$92.22M$80.63M$79.73M$75.37M$98.49M$80.56M$94.84M$116.22M$120.37M$94.66M$99.25M$80.56M$83.94M$68.15M$71.10M$58.05M$49.21M$44.10M
Low Forecast$97.62M$94.01M$90.95M$83.73M$79.90M$76.44M$81.52M$70.63M$75.59M$71.92M$98.49M$80.56M$83.89M$116.22M$106.41M$83.68M$87.74M$80.56M$83.94M$68.15M$71.10M$58.05M$49.21M$44.10M
# Analysts333344466354845443435454
Surprise %------------1.11%0.84%1.02%0.96%1.04%1.10%1.23%1.11%1.10%1.17%1.35%-

Beauty Health Company's average Quarter revenue forecast for Mar 24 based on 4 analysts is $80.56M, with a low forecast of $80.56M, and a high forecast of $80.56M. SKIN's average Quarter revenue forecast represents a -16.78% decrease compared to the company's last Quarter revenue of $96.80M (Dec 23).

Beauty Health Company EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts333344466354845443435454
EBITDA------------$-18.40M$-70.50M$-13.15M$-12.50M$530.00K$-1.63M$2.83M$-7.85M$-10.11M$-211.20M$-135.49M$22.98M
Avg Forecast$-16.36M$-15.76M$-15.24M$-14.03M$-13.39M$-12.81M$-13.66M$-11.96M$-12.01M$-11.43M$-15.29M$-12.51M$-13.54M$-18.04M$-17.84M$-14.03M$-14.71M$-7.59M$-7.91M$-6.42M$-6.70M$-5.47M$-325.18M$-4.16M
High Forecast$-15.15M$-14.59M$-14.12M$-13.00M$-12.40M$-11.87M$-12.66M$-10.96M$-11.73M$-11.16M$-15.29M$-12.51M$-13.02M$-18.04M$-16.52M$-12.99M$-13.62M$-7.59M$-7.91M$-6.42M$-6.70M$-5.47M$-260.15M$-4.16M
Low Forecast$-17.14M$-16.51M$-15.97M$-14.70M$-14.03M$-13.42M$-14.32M$-12.52M$-12.38M$-11.70M$-15.29M$-12.51M$-14.72M$-18.04M$-18.69M$-14.69M$-15.41M$-7.59M$-7.91M$-6.42M$-6.70M$-5.47M$-390.22M$-4.16M
Surprise %------------1.36%3.91%0.74%0.89%-0.04%0.21%-0.36%1.22%1.51%38.61%0.42%-5.53%

4 analysts predict SKIN's average Quarter EBITDA for Mar 23 to be $-14.03M, with a high of $-12.99M and a low of $-14.69M. This is -2746.37% lower than Beauty Health Company's previous annual EBITDA (Dec 22) of $530.00K.

Beauty Health Company Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts333344466354845443435454
Net Income------------$-9.40M$-73.80M$3.36M$-22.20M$3.81M$131.00K$7.93M$32.51M$-17.31M$-215.15M$-139.38M$13.64M
Avg Forecast$14.89M$12.41M$9.92M$7.44M$-4.76M$-4.96M$-4.55M$-10.13M$-13.34M$-11.45M$-1.87M$-12.87M$-9.15M$9.19M$5.80M$-3.51M$4.88M$1.50M$-903.23K$457.86K$-523.00K$-1.96M$-334.51M$-3.55M
High Forecast$15.81M$13.17M$10.54M$7.90M$-4.30M$-4.49M$-4.11M$-6.45M$-10.67M$-10.35M$-1.69M$-11.64M$-7.49M$9.19M$6.16M$-3.18M$5.18M$1.50M$-903.23K$457.86K$-523.00K$-1.96M$-267.61M$-3.55M
Low Forecast$13.46M$11.22M$8.97M$6.73M$-5.05M$-5.27M$-4.83M$-13.82M$-16.00M$-12.16M$-1.98M$-13.67M$-11.65M$9.18M$5.25M$-3.73M$4.41M$1.50M$-903.23K$457.86K$-523.00K$-1.96M$-401.41M$-3.55M
Surprise %------------1.03%-8.03%0.58%6.32%0.78%0.09%-8.78%71.00%33.10%109.84%0.42%-3.84%

Beauty Health Company's average Quarter net income forecast for Sep 23 is $9.19M, with a range of $9.18M to $9.19M. SKIN's average Quarter net income forecast represents a 173.08% increase compared to the company's last Quarter net income of $3.36M (Jun 23).

Beauty Health Company SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts333344466354845443435454
SG&A------------$61.00M$67.70M$78.14M$69.10M$67.49M$63.55M$72.47M$62.67M$62.10M$49.65M$70.62M$17.70M
Avg Forecast$72.51M$69.83M$67.56M$62.19M$59.35M$56.78M$60.56M$53.02M$53.24M$50.67M$67.76M$55.42M$60.01M$79.96M$79.04M$62.16M$65.17M$55.13M$57.45M$46.64M$48.66M$39.73M$33.68M$30.18M
High Forecast$75.97M$73.16M$70.78M$65.16M$62.18M$59.49M$63.45M$55.48M$54.85M$51.85M$67.76M$55.42M$65.25M$79.96M$82.81M$65.13M$68.28M$55.13M$57.45M$46.64M$48.66M$39.73M$33.68M$30.18M
Low Forecast$67.16M$64.68M$62.57M$57.60M$54.97M$52.59M$56.09M$48.59M$52.00M$49.48M$67.76M$55.42M$57.71M$79.96M$73.21M$57.57M$60.36M$55.13M$57.45M$46.64M$48.66M$39.73M$33.68M$30.18M
Surprise %------------1.02%0.85%0.99%1.11%1.04%1.15%1.26%1.34%1.28%1.25%2.10%0.59%

Beauty Health Company's average Quarter SG&A projection for Mar 24 is $55.42M, based on 4 Wall Street analysts, with a range of $55.42M to $55.42M. The forecast indicates a -9.14% fall compared to SKIN last annual SG&A of $61.00M (Dec 23).

Beauty Health Company EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts333344466354845443435454
EPS------------$-0.07$-0.56$0.03$-0.17$0.03-$0.05$0.22$-0.12$-1.63$-1.52$0.11
Avg Forecast$0.12$0.10$0.08$0.06$-0.04$-0.04$-0.04$-0.08$-0.11$-0.09$-0.02$-0.10$-0.07$0.07$0.05$-0.03$0.04$0.01$-0.01-$-0.00$-0.01-$-0.03
High Forecast$0.13$0.11$0.08$0.06$-0.03$-0.04$-0.03$-0.05$-0.09$-0.08$-0.01$-0.09$-0.06$0.07$0.05$-0.03$0.04$0.01$-0.01-$-0.00$-0.01-$-0.03
Low Forecast$0.11$0.09$0.07$0.05$-0.04$-0.04$-0.04$-0.11$-0.13$-0.10$-0.02$-0.11$-0.09$0.07$0.04$-0.03$0.04$0.01$-0.01-$-0.00$-0.01-$-0.03
Surprise %------------0.99%-7.56%0.54%6.00%0.76%0.09%-7.86%68.20%32.56%118.11%-562.13%-4.35%

According to 4 Wall Street analysts, Beauty Health Company's projected average Quarter EPS for Sep 23 is $0.07, with a low estimate of $0.07 and a high estimate of $0.07. This represents a 192.69% increase compared to SKIN previous annual EPS of $0.03 (Jun 23).

Beauty Health Company Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GXOGXO Logistics$46.95$64.2536.85%Buy
YOUClear Secure$26.67$34.5029.36%Buy
LPROOpen Lending$6.56$8.0021.95%Hold
FIGSFIGS$5.91$7.0018.44%Hold
DOCSDoximity$52.70$53.381.29%Buy
SKINBeauty Health Company$1.61$1.00-37.89%Buy

SKIN Forecast FAQ


Is Beauty Health Company a good buy?

Yes, according to 3 Wall Street analysts, Beauty Health Company (SKIN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of SKIN's total ratings.

What is SKIN's price target?

Beauty Health Company (SKIN) average price target is $1 with a range of $1 to $1, implying a -31.51% from its last price of $1.46. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Beauty Health Company stock go up soon?

According to Wall Street analysts' prediction for SKIN stock, the company can go down by -31.51% (from the last price of $1.46 to the average price target of $1), down by -31.51% based on the highest stock price target, and down by -31.51% based on the lowest stock price target.

Can Beauty Health Company stock reach $2?

SKIN's average twelve months analyst stock price target of $1 does not support the claim that Beauty Health Company can reach $2 in the near future.

What are Beauty Health Company's analysts' financial forecasts?

Beauty Health Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $333.9M (high $349.71M, low $308.5M), average EBITDA is $-51.833M (high $-47.89M, low $-54.287M), average net income is $-24.398M (high $-19.345M, low $-28.966M), average SG&A $229.72M (high $240.6M, low $212.24M), and average EPS is $-0.197 (high $-0.156, low $-0.233). SKIN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $395.5M (high $414.36M, low $366.3M), average EBITDA is $-61.395M (high $-56.862M, low $-64.323M), average net income is $44.66M (high $47.43M, low $40.37M), average SG&A $272.1M (high $285.07M, low $252.01M), and average EPS is $0.36 (high $0.382, low $0.325).

Did the SKIN's actual financial results beat the analysts' financial forecasts?

Based on Beauty Health Company's last annual report (Dec 2023), the company's revenue was $397.99M, which missed the average analysts forecast of $408.69M by -2.62%. Apple's EBITDA was $-131M, beating the average prediction of $-63.442M by 106.36%. The company's net income was $-100M, missing the average estimation of $2.33M by -4405.21%. Apple's SG&A was $275.93M, missing the average forecast of $281.17M by -1.87%. Lastly, the company's EPS was $-0.76, missing the average prediction of $0.0187 by -4154.41%. In terms of the last quarterly report (Dec 2023), Beauty Health Company's revenue was $96.8M, beating the average analysts' forecast of $87.22M by 10.98%. The company's EBITDA was $-18.4M, beating the average prediction of $-13.54M by 35.89%. Beauty Health Company's net income was $-9.4M, beating the average estimation of $-9.151M by 2.72%. The company's SG&A was $61M, beating the average forecast of $60.01M by 1.65%. Lastly, the company's EPS was $-0.073, missing the average prediction of $-0.0738 by -1.04%